Plain-English translation of NCT05789043 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether —a medication that helps your immune system fight cancer—works better when combined with two other drugs (apatinib and temozolomide) to treat advanced acral melanoma, a type of skin cancer that grows on the palms, soles, or under the nails. Right now, doctors are not sure which combination of these three drugs works best as a first treatment. This study will compare different combinations to see which helps patients live longer without their cancer getting worse.
Acral melanoma is a particularly aggressive form of skin cancer that is hard to treat, and people with advanced cases don't have many proven treatment options. Researchers believe this medication, especially when combined with other drugs, might give patients a better chance of controlling their cancer and living longer.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive one of three different treatment combinations—either all three medications together, two of the medications, or one medication alone. You will visit the clinic regularly for blood tests, scans, and check-ups to see how well the treatment is working and to monitor for any side effects. The study will track how long it takes before your cancer starts growing again and how you feel during treatment.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Peking University Cancer Hospital & Institute
Enrollment target
~140 participants
Started
March 2023
Primary completion
August 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jun Guo, Dr
Peking University Cancer Hospital & Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.